Assuntos
Dislipidemias/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Transporte Biológico , Colesterol/sangue , Proteínas de Transferência de Ésteres de Colesterol/antagonistas & inibidores , HDL-Colesterol/administração & dosagem , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Suplementos Nutricionais , Dislipidemias/sangue , Mutação com Ganho de Função , Humanos , Hipolipemiantes/farmacologia , Receptores X do Fígado/agonistas , Niacina/uso terapêutico , Oligorribonucleotídeos Antissenso/uso terapêutico , Inibidores de PCSK9 , Pró-Proteína Convertase 9/sangue , Pró-Proteína Convertase 9/genética , Proteínas Recombinantes/administração & dosagemRESUMO
BACKGROUND/OBJECTIVES: Front-of-pack nutrition labels can help consumers to make healthier choices and stimulate healthier product development. This is the first modeling study to investigate the potential impact on cholesterol levels of consuming a diet consisting of products that comply with the criteria for a 'healthier choice logo'. SUBJECTS/METHODS: National food consumption and food composition data were used to estimate the nutrient intake of the Dutch adult population (18-70 years) before and after replacing foods that did not comply with the choices front-of-pack label criteria. Different scenarios were established. The difference in cholesterol levels in the Dutch population was assessed before and after replacement by means of equations from meta-analyses that calculate how blood lipids change when diet composition changes. RESULTS: After replacing non-complying products with products, which comply with the label's criteria (maximum scenario), saturated fatty acids median intake reduced from 14.5 to 9.8 en%. Trans-fatty acids reduced from 0.95 to 0.57 en%. The average predicted changes in low-density lipoprotein and total cholesterol levels were -0.25 and -0.31 mmol/l, respectively. Because high-density lipoprotein (HDL) cholesterol levels reduced as well (-0.05 mmol/l), overall, the result was a slightly positive change in the total cholesterol/HDL ratio (-0.03). CONCLUSIONS: Our findings suggest that the consumption of foods complying with the criteria for a front-of-pack label could contribute moderately to cardiovascular risk reduction via influencing blood lipids. These findings were independent of other potential effects on related health outcomes.
Assuntos
HDL-Colesterol/sangue , LDL-Colesterol/sangue , Dieta , Gorduras na Dieta/administração & dosagem , Rotulagem de Alimentos , Adolescente , Adulto , Idoso , Doenças Cardiovasculares/prevenção & controle , HDL-Colesterol/administração & dosagem , LDL-Colesterol/administração & dosagem , Ingestão de Energia , Ácidos Graxos/análise , Humanos , Pessoa de Meia-Idade , Países Baixos , Fatores de Risco , Ácidos Graxos trans/administração & dosagem , Triglicerídeos/sangue , População Branca , Adulto JovemRESUMO
High-density lipoprotein (HDL) plays a key role in reverse cholesterol transport but also activates nitric oxide synthase and stimulates prostacyclin release, enhances endothelial repair, inhibits cell adhesion molecule expression on vascular endothelium and monocyte recruitment into the arterial wall, and exerts antithrombotic effects. In experimental animals, infusions of HDL or apolipoprotein A-1 (apoA-1) halt the progression or induce regression of atherosclerosis, with favorable effects on plaque composition. Remarkably, a benefit is observed after a single infusion. In a pilot study, weekly infusions of ETC-216, a formulation of recombinant apoA-1 Milano, were administered at two doses for 5 weeks to patients beginning within 2 weeks of an acute coronary syndrome (ACS). Among the 47 patients completing the study, percent atheroma volume by intracoronary ultrasound was reduced in the combined active treatment groups but not in the placebo group. In a larger trial, the Effect of rHDL on Atherosclerosis-Safety and efficacy (ERASE), 183 post-ACS patients were randomized to 4 weekly infusions of placebo or one of two doses of CSL-111, which consists of apoA-1 derived from human plasma and combined with soybean phosphatidylcholine. The greater dose was discontinued because of a high incidence of hepatic enzyme elevation. Among the 136 patients with evaluable end point data, percent change in atheroma volume, the primary endpoint, improved significantly in the CSL-111 group but not in the placebo group. The secondary end points of plaque characterization indices and quantitative coronary angiographic changes both improved significantly in the CSL-111 group compared with the group receiving placebo. Taken together, this evidence suggests that infusions of HDL or apoA-1 may reduce events, particularly among patients with ACS.